Impact of a health safety warning and prior authorisation on the use of piroxicam: A time-series study

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 3, 2012, Pages 281-284

  Carracedo Martínez, Eduardo ^a   Pia Morandeira, Agustin ^a   Figueiras, Adolfo ^b  

^a Galician Health Service   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Drug utilisation; Peptic ulcer; Piroxicam

Indexed keywords

PIROXICAM;

ARTICLE; DRUG APPROVAL; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; HUMAN; PRIORITY JOURNAL; SPAIN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PIROXICAM; REGRESSION ANALYSIS; SAFETY; SPAIN;

EID: 84858298515     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2275     Document Type: Article

References (15)

1. Snell ES. Regulatory decisions and the pharmaceutical industry. Med Toxicol 1986; 1(Suppl 1): 130-6.
2. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312(7046): 1563-6.
3. García Rodríguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997; 26(Suppl 1): 16-20.
4. Laporte JR, Carné X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan countries study on upper gastrointestinal bleeding. Lancet 1991; 337(8733): 85-9.
5. Romo Avilés C, Martín Calero MJ, Motilva Sánchez V, et al. Uso racional de antiinflamatorios no esterioideos en atención primaria. Aten Primaria 1998; 22(3): 177-80.
6. Bergman U, Andersen M, Vaccheri A, et al. Deviations from evidence-based prescribing of non-steroidal anti-inflammatory drugs in three European regions. Eur J Clin Pharmacol 2000; 56(3): 269-72.
7. Peiro S, Cervera P. Desde los AINE recomendados a la recomendación de los AINE. Gac Sanit 2005; 19(6): 488-489.
8. Fernandez-Silva M. Influencia del visado de inspección y de una alerta sanitaria sobre la utilización de tacrolimus y pimecrolimus tópicos. Farm Aten Primaria 2007; 5(1): 8-15.
9. Fischer MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004; 351(21): 2187-94.
10. Roughead EE, Zhang F, Ross-Degnan D, et al. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors. Med Care 2006; 44(4): 378-82.
11. Wilkinson JJ, Force RW, Cady PS. Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy 2004; 24: 978-86.
12. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008; 179(5): 438-46.
13. Carracedo-Martinez E, Pia-Morandeira A. Impacto de una alerta sanitaria sobre la utilización de ranelato de estroncio. Gac Sanit 2010; 24: 151-3.
14. Gleason PP, Walters C, Heaton AH, et al. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. J Manag Care Pharm 2007; 13: 420-5.
15. Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008; 14: 523-531.